Results 91 to 100 of about 56,503 (261)

Pneumococcal carriage, serotype distribution and risk factors in children with community-acquired pneumonia, 5 years after introduction of the 10-valent pneumococcal conjugate vaccine in Ethiopia [PDF]

open access: yes, 2019
Background: There is a scarcity of data on pneumococcal serotypes carried by children in Ethiopia. We studied pneumococcal nasopharyngeal carriage rate, serotypes, and risk factors among children with community acquired pneumonia (CAP).
Abebe, Workeabeba   +7 more
core   +1 more source

Oral Microbiota Linking Humoral Response, Periodontitis and Atherosclerosis

open access: yesJournal of Clinical Periodontology, Volume 52, Issue 11, Page 1550-1559, November 2025.
ABSTRACT Aim The humoral immune system is implicated in the link between periodontitis and atherosclerosis. This study aims to explore how interactions between the oral microbiota and humoral immune responses may contribute to this association. Materials and Methods We analysed data from the Northern Finland Birth Cohort 1966, which included 1560 ...
Ramin Akhi   +12 more
wiley   +1 more source

Nonencapsulated Streptococcus pneumoniae: Emergence and Pathogenesis

open access: yesmBio, 2016
While significant protection from pneumococcal disease has been achieved by the use of polysaccharide and polysaccharide-protein conjugate vaccines, capsule-independent protection has been limited by serotype replacement along with disease caused by ...
Lance E. Keller   +2 more
doaj   +1 more source

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 39, Issue 11, Page 1881-1894, November 2025.
When managing psoriasis, induced or exacerbated by ICI therapy for cancer, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis and the potential impact on ICI efficacy. No direct, high‐level evidence exists to address these concerns.
Kim A. Papp   +14 more
wiley   +1 more source

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly [PDF]

open access: yes, 2018
Background: Pneumonia is one of the leading causes of mortality and has a high burden in morbidity. In Portugal, 7-valent pneumococcal conjugated vaccine (PCV) was used since 2001 and PCV10/13 since 2009, being the last introduced into the National ...
Froes, Filipe   +6 more
core   +2 more sources

Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance [PDF]

open access: yes, 2012
SCOPUS: re.jinfo:eu-repo/semantics ...
Hanquet, Germaine, Vergison, Anne
core   +1 more source

The New Era of Pneumococcal Vaccination in Adults: What Is Next?

open access: yesVaccines
Streptococcus pneumoniae remains the leading cause of community-acquired pneumonia in adults and bacterial meningitis in children worldwide. In addition to pneumonia, invasive pneumococcal diseases (IPDs), such as bacteremia and meningitis, pose a ...
Lale Ozisik
doaj   +1 more source

Wandering Spleen, A Rare Cause of Acute Abdomen: A Case Report

open access: yesClinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT A wandering spleen (WS) is rare and often presents a diagnostic challenge to clinicians. We report a WS in a 16‐year‐old who presented with abdominal pain, vomiting, and peritonism. Imaging (ultrasound and CT scans), which usually facilitates a prompt diagnosis, was inconclusive, and the diagnosis was made by exploratory laparotomy.
John Kanyiri Yambah   +7 more
wiley   +1 more source

Emerging Challenges and Opportunities in Infectious Disease Epidemiology. [PDF]

open access: yes, 2019
Much of the intellectual tradition of modern epidemiology stems from efforts to understand and combat chronic diseases persisting through the 20th century epidemiologic transition of countries such as the United States and United Kingdom.
Lewnard, Joseph A, Reingold, Arthur L
core  

Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction [PDF]

open access: yes, 2019
Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies.
Bernstein, David I.   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy